Algen Biotechnologies
Algen is using CRISPR to uncover disease-driving RNA messages to find treatments for cancer, inflammation and diseases with high unmet needs. We are harnessing the power of CRISPR and machine learning to find first-in-class drugs that modulate RNA messages at single-cell resolution. Algen's founders are bioengineer from Jennifer Doudna Lab and biotech commercialization expert, teamed up with experienced pharmaceutical executives.
Vendors
0Third parties this company currently discloses, grouped by function when classified.
No disclosed vendors yet
Vendors appear only once a public disclosure or other published evidence names them.
Customers
0Companies whose current disclosures name this company as a vendor.
No observed customers yet
Customers appear when another company's current disclosure names this company as a vendor.
Potential customers
0Companies using another vendor in one of Algen Biotechnologies’s categories, excluding Algen Biotechnologies’s observed customers.
No potential customers found
Potential customers appear after Algen Biotechnologies has a category assignment and current vendor relationships can be compared.